introduction pleomorphic adenoma common neoplasm arising salivary glands surgical management primary therapeutic modality use modern surgical techniques recurrence infrequent facial nerve sparing norm patients recurrent disease risk relapses increased surgical resection particularly patients multiple recurrences occurred role adjuvant radiotherapy setting remains uncertain neutron radiotherapy superior conventional radiotherapy malignant salivary gland tumors role treatment pleomorphic adenomas defined report experience using modality recurrent pleomorphic adenomas methods sixteen patients treated neutron radiotherapy recurrent pleomorphic adenomas major salivary glands NUMBER NUMBER median age diagnosis NUMBER years range years median age time neutron radiotherapy NUMBER years range years median number prior surgical procedures NUMBER range median duration initial diagnosis radiotherapy NUMBER years range NUMBER years median NUMBER months range months median period risk survivors NUMBER months defined interval completion neutron radiotherapy patients evidence gross residual disease time treatment determined imaging studies patients having multinodular disease results actuarial survival NUMBER patient died lung metastases NUMBER months treatment patient died liver tumor uncertain origin histology rule metastasis previous pleomorphic adenoma patient died recurrent disease base skull actuarial locoregional control rate NUMBER patients locoregional recurrence malignant transformation adenocarcinoma statistical difference actuarial survival NUMBER vs NUMBER p NUMBER comparing patients gross residual disease vs microscopic residual disease actuarial locoregional control NUMBER patients gross residual disease vs NUMBER microscopic disease actuarial risk nonaudiologic grade complications NUMBER facial nerve injuries observed direct consequence neutron radiotherapy conclusions neutron radiotherapy offers excellent local control rates survival rates patients multiply recurrent pleomorphic adenomas candidates surgical resection presence gross residual disease morbidity acceptable malignant transformations metastases uncommon observed tumor copyright NUMBER john wiley sons high risk NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER months NUMBER follow NUMBER NUMBER follow NUMBER year NUMBER year NUMBER year NUMBER year NUMBER year treatment related rtog estro iii iv